FAST NEWS: Legend Biotech Pares Losses on Milestone Revenue
The latest: Legend Biotech Corp. (LEGN.US), a cell therapy subsidiary of Genscript Biotech Corp. (1548.HK), reported a loss of $41.09 million in the first quarter, half the $80.9 million loss from the same…
Recent Articles
RELATED ARTICLES
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK -
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
